March 27, 2020 -- Medical simulation software company Simulations Plus announced that it has created a program to speed up consulting assistance to scientists working on COVID-19 research.
As part of its StrategiesPlus COVID-19 ACT program, each division of the company will provide specialized expertise to help develop safe, effective treatments. It offers the following:
- Mechanistic GastroPlus pulmonary simulations to investigate alternative dosing modalities and optimize dosing to target lung exposure
- Application of GastroPlus modeling and simulation data in regulatory reports to support repurposing strategies or drug product quality claims
- Utilization of quantitative systems toxicology and pharmacology models from drug-induced liver injury modeling software to predict potential liver toxicity risk, efficacy potential for pulmonary injury-related pathophysiology, or efficacy potential for cardiac injury-related pathophysiology of drug candidate treatments for COVID-19
- Semi-mechanistic drug and disease modeling and simulation support, including implementation of viral dynamics models for clinical and strategic decision-making and regulatory submissions
- Comprehensive clinical pharmacology consulting for drug development and regulatory interaction
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
